E1512 – A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC
Newsletter Feature Article:
- E1512 Trial Spotlight: a Q and A with study chair Joel Neal, MD, PhD, Stanford University/Stanford Cancer Institute, published in the May 2013 issue of “News from ECOG-ACRIN.”
Physician and Research Staff Educational Materials:
These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.
- Pocket Reference: trial schema, study objectives, and eligibility requirements on a pocket-sized card for easy reference when consulting with patients in the office or on rounds.
- Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study intended for promotional use among health care professionals.
Additional Information at ClinicalTrials.gov: